Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 44 | SFEBES2016 | Next issue

Society for Endocrinology BES 2016

Brighton, UK
07 Nov 2016 - 09 Nov 2016

Card image cap
07 Nov 2016 to 09 Nov 2016 Brighton, UK Further information

Oral Communications

Thyroid and Neoplasia

ea0044oc3.1 | Thyroid and Neoplasia | SFEBES2016

Frequent Occurrence of DUOX2 and DUOXA2 Mutations in Cases with Borderline Bloodspot Screening TSH who Develop ‘True’ Congenital Hypothyroidism

Peters Catherine , Nicholas Adeline K , Lyons Greta , Langham Shirley , Serra Eva , Schoenmakers Erik , Muzza Marina , Fugazzola Laura , Schoenmakers Nadia

The UK newborn screening programme for congenital hypothyroidism (CH) facilitates prevention of neurodevelopmental delay in CH by enabling prompt diagnosis and treatment. Although the UK Newborn Screening Programme Centre (UKNSPC) defines a borderline bloodspot screening TSH (bsTSH) concentration as 10–20 mU/l, the lower cutoff used at Great Ormond Street Hospital (6 mU/l), enables diagnosis of true and transient CH in cases missed using UKNSPC criteria. We hypothesised t...

ea0044oc3.2 | Thyroid and Neoplasia | SFEBES2016

Pharmacological enhancement of radioiodine uptake through Src kinase inhibition

Poole Vikki , Fletcher Alice , Modasia Bhavika , Sharma Neil , Thompson Rebecca , Nieto Hannah , Imruetaicharoenchoke Waraporn , Read Martin , Boelaert Kristien , McCabe Christopher , Smith Vicki

In thyroid cancer, a reduction in sodium iodide symporter (NIS) expression at the basolateral plasma membrane (PM) of thyrocytes decreases the efficacy of radioiodine imaging, ablative therapy and treatment of metastases. NIS overexpression in breast cancer has resulted in radioiodine being widely proposed as a novel therapeutic strategy. However, uptake is insufficient for tumour destruction. Augmenting NIS PM localisation represents an important therapeutic strategy for incr...

ea0044oc3.3 | Thyroid and Neoplasia | SFEBES2016

Post-Radioiodine Graves’ Management: The Pragma-Study

Perros Petros , Dayan Colin , Vaidya Bijay , Williams Graham , Lazarus John H , Hickey Janis , Willis Debbie , Archer Natasha , Franklyn Jayne , Basu Ansu

Introduction: Radioiodine (RI) is a safe and effective treatment for Graves’ disease. In the months following RI different strategies are used to gain control of thyroid status, although there is no evidence base as to the optimal approach.Objectives: To compare the incidence of dysthyroidism post-RI between three principal management strategies employed by clinicians.Study design and methods: Retrospective, observational, mul...

ea0044oc3.4 | Thyroid and Neoplasia | SFEBES2016

Identification of novel sodium iodide symporter (NIS) interactors which modulate iodide uptake

Fletcher Alice , Poole Vikki , Modasia Bhavika , Imruetaicharoenchoke Waraporn , Thompson Rebecca , Sharma Neil , Nieto Hannah , Read Martin , Turnell Andrew , Boelaert Kristien , Smith Vicki , McCabe Christopher

By exploiting the canonical function of the sodium iodide symporter (NIS) ablative radioiodine therapy is an effective treatment for thyroid cancer. However, a subset of patients are unable to accumulate sufficient radioiodine for effective treatment due to the dysregulation of NIS, which can occur through decreased expression and/or reduced plasma membrane localisation. Although NIS localisation at the plasma membrane is critical for radioiodine uptake the mechanism of NIS tr...

ea0044oc3.5 | Thyroid and Neoplasia | SFEBES2016

Identification of murine neuroendocrine tumour (NET) cell binding peptides identified through phage display

Stevenson Mark , Javid Mahsa , Lines Kate , Thakker Rajesh

Neuroendocrine tumours (NETs) may occur in multiple sites including, the pancreas, gastrointestinal tract, lung, thymus, adrenals and pituitary, and as part of the multiple endocrine neoplasia type 1 (MEN1) syndrome. Current treatments for advanced NETs, rarely achieve a cure due to metastases at presentation and therefore additional treatments are required. Identification of cell surface receptors or binding sites that are unique to NETs could lead to novel targeted drugs, ra...

ea0044oc3.6 | Thyroid and Neoplasia | SFEBES2016

Oestrogens Stimulate Proliferation in Colorectal Cancer via GPER and the Hippo signalling pathway

Arvaniti Anastasia , Gilligan Lorna , Rahman Habibur , Gondal Ali , Foster Paul

Circulating oestrogen concentrations affect the incidence of and outcomes for patients with colorectal cancer (CRC). We have previously shown that steroid sulphatase (STS), the fundamental enzyme that liberates conjugated oestrogens into their active forms, is significantly elevated in human CRC tissue. Here we demonstrate that elevated STS activity correlates to increased CRC proliferation, and that these effects are mediated through G-protein coupled oestrogen receptor (GPER...